ClinicalTrials.gg
CompletedNCT02075255Updated Jun 8, 2018Results posted

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

A Phase 3 interventional study of Benralizumab and Placebo in Asthma, sponsored by AstraZeneca. Completed at 87 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-06-08.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
12th of 39
220 · median 128
Started
2014
with 1 other
Phase 3
20 of 39
1 open now
Registered
10th of 39
by date
Lead sponsor
24 of 39
AstraZeneca

Among the 39 studies testing benralizumab in Asthma, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 20 in phase 3, and was the 10th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.

03

Conditions studied

  • Asthma

Keywords

  • Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive Lung Diseases, OCS, Oral Corticosteroids
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Female and male aged from 18 to 75 years, inclusively.
  3. History of physician-diagnosed asthma requiring treatment with medium dose ICS and LABA.
  4. Elevated level of peripheral blood eosinophil
  5. Documented treatment with high-dose ICS and LABA for at least 6 months prior to Visit 1
  6. Chronic oral therapy for at least 6 continuous months directly preceding Visit 1. Subjects must be on doses equivalent to 7.5 - 40 mg/day of prednisolone/prednisone at Visit 1 and be on a stable dose for at least 2 weeks prior to randomization. Patients must agree to switch to study required prednisone/prednisolone as their oral corticosteroid for the duration of the study.
  7. Patients with documented failures of OCS reduction within 6 months prior to Visit 1 will not be required to proceed through the dose optimization phase during run-in.
  8. Morning pre-bronchodilator (Pre-BD) of \<80% predicted
  9. Evidence of asthma as documented by either:

    Airway reversibility (FEV1 ≥12% and 200 mL) demonstrated at Visit 1, Visit 2, or Visit 3 using the Maximum Post-bronchodilator Procedure OR Documented reversibility in the previous 24 months prior to Visit 1 OR Airway hyperresponsiveness (PC20 FEV1 methacholine concentration ≤8mg/mL) documented in the previous 12 months prior to planned date of randomization OR Airflow variability in clinic FEV1 ≥20% between 2 consecutive clinic visits documented in the 12 months prior to the planned date of randomization (FEV1 recorded during an exacerbation should not be considered for this criterion).

    All patients must have reversibility testing performed before randomization to establish a baseline characteristic.

    If patients do not demonstrate airway reversibility at either Visit 1 or Visit 2 and this is needed to qualify the patient for randomization, the site should reiterate the need to withhold short- and long-acting bronchodilators prior to Visit 3 in an effort to meet this inclusion criterion.

  10. At least 1 documented asthma exacerbation in the previous 12 months prior to the date informed consent is obtained
  11. Optimized OCS dose reached at least 2 weeks prior to randomization
  12. Additional asthma controller medication must not have been initiated during run in/optimization period (not applicable for management of exacerbations during screening/ run in optimization phase)
  13. At least 70% compliance with OCS use
  14. At least 70% compliance with usual asthma controller ICS-LABA
  15. Minimum 70% (i.e. 10 of 14 days) compliance with asthma daily diary (morning and evening diary)

Exclusion criteria

Exclusion criteria:

  1. pulmonary disease other than asthma or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts.
  2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:

    • Affect the safety of the patient throughout the study
    • Influence the findings of the studies or their interpretations
    • Impede the patient's ability to complete the entire duration of study
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date is obtained or during the screening/run-in period
  4. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during run-in/optimization period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
  5. History of life-threatening asthma
  6. Asthma control reached at an OCS dose of ≤5mg during run-in/OCS optimization phase
  7. Qualifies for 3 consecutive dose reductions at Visits 2-4 and continues to meet OCS dose reduction criteria at Visit 5
  8. Receipt of oral , other than prednisone or prednisolone, as the maintenance oral steroid controller for asthma symptoms from Visit 1 and throughout the study.
  9. (ALT) or aspartate aminotransferase (AST) level ≥2.5 times the (ULN) confirmed during screening period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Benralizumab Arm A

    Benralizumab administered subcutaneously every 4 weeks

    Biological: Benralizumab

  • Experimental
    Benralizumab Arm B

    Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously every 4 weeks

    Biological: Placebo

Interventions

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously every 4 weeks

  • BiologicalPlacebo

    Placebo subcutaneously on study week 0 until study week 24 inclusive.

  • BiologicalBenralizumab

    Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.

06

What researchers measure

Primary outcomes

  1. Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control

    Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

Secondary outcomes

  1. Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control

    Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.

    Time frame: Week 28

  2. Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL

    Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

  3. The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control

    Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

  4. The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control

    Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

  5. The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.

    Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

  6. The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control

    Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

    Time frame: Week 28

  7. Number and Percentage of Patients With ≥1 Asthma Exacerbation

    Number and percentage of patients with at least one post randomisation asthma exacerbation.

    Time frame: Immediately following the randomisation through Study Week 28

  8. Time to the First Asthma Exacerbation

    Time to the first occurrence of asthma exacerbation post randomisation

    Time frame: The time from randomisation to the date of first asthma exacerbation over 28 weeks

  9. Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit

    Time to the first exacerbation requiring hospitalization or ER visit post randomisation

    Time frame: The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.

  10. The Annualized Rate of Asthma Exacerbation

    The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.

    Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up

  11. The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization

    The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.

    Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up

  12. Number of Days in Hospital Due to Asthma

    Number of days in hospital due to asthma, if none, 0 day is considered

    Time frame: The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up

  13. Change From Baseline to Week 28 in Pre-bronchodilator FEV1

    Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.

    Time frame: Change from baseline at week 28

  14. Change From Baseline to Week 28 in Asthma Symptom Scores (Total)

    Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Change from baseline at week 28

  15. Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)

    Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Change from baseline at week 28

  16. Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)

    Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

    Time frame: Change from baseline at week 28

  17. Change From Baseline to Week 28 in Rescue Medication Use

    Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of day inhaler puffs + 2 x \[number of day nebulizer times\].

    Time frame: Change from baseline at week 28

  18. Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)

    Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.

    Time frame: Change from baseline at week 28

  19. Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)

    Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data

    Time frame: Change from baseline at week 28

  20. Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication

    Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.

    Time frame: Change from baseline at week 28

  21. Change From Baseline to Week 28 in ACQ-6

    ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

    Time frame: Change from baseline at week 28

  22. ACQ-6 Responders (Improvement) at Week 28

    Improvement is defined as ACQ-6 (End of treatment - baseline) \<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.

    Time frame: Week 28

  23. Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)

    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

    Time frame: Change from baseline at week 28

  24. AQLQ(s)+12 Responders (Improvement) at Week 28

    AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.

    Time frame: Week 28

  25. Extent of Exposure

    Duration of exposure from first dose date to last dose date.

    Time frame: From first dose to Week 24

  26. Serum Concentration of Benralizumab

    Pre-dose serum concentrations at each visit

    Time frame: Pre-first dose to Week 36

  27. Anti-drug Antibody Response

    Number and percentage of patients in different ADA response categories

    Time frame: From baseline to follow-up Week 36

  28. Percent Change From Baseline in Blood Eosinophil Counts

    Percent change from baseline in blood eosinophil counts at week 28

    Time frame: Change from baseline at Week 28

  29. Total Lung Capacity

    Change from baseline in total lung capacity

    Time frame: From baseline to Week 28

  30. Residual Volume

    Change from baseline in residual volume

    Time frame: From baseline to Week 28

  31. Vital Capacity

    Change from baseline in vital capacity

    Time frame: From baseline to Week 28

  32. Functional Residual Capacity

    Change from baseline in functional residual capacity

    Time frame: From baseline to Week 28

  33. Inspiratory Capacity

    Change from baseline in inspiratory capacity

    Time frame: From baseline to Week 28

07

Results

Posted Oct 17, 2017

Participant flow

Participant flow — Overall Study
MilestoneBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Started727375
Completed686972
Not completed443
Withdrew: Study specific withdrawal criteria011
Withdrew: Withdrawal by subject410
Withdrew: Lost to follow-up001
Withdrew: Adverse event001
Withdrew: Death020

Outcome measures

PrimaryPercentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control

Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Median · Percent
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control
PercentBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control75.00 (50.00 to 83.30)75.00 (60.00 to 87.50)25.00 (0.00 to 33.30)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 33.3 · 95% CI 16.70 to 50.00Hodges-Lehmann estimate is used.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 37.50 · 95% CI 20.80 to 50.00Hodges Lehmann estimate is used.
SecondaryNumber and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control

Number and percentage of patients in different categories of percent reduction from baseline in final OCS dose.

Time frame:
Week 28
Reported as:
Count of participants · Participants
Number and Percentage of Patients in Different Categories of Percent Reduction From Baseline in Final OCS Dose While Maintaining Asthma Control
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
>=90% reduction24279
>=75% reduction383715
>=50% reduction484828
>0% reduction555840
No change or any increase171535
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · proportional odds model · p = <0.001 · Odds ratio (or): 4.09 · 95% CI 2.22 to 7.57Controlling for treatment group, region, and baseline OCS dose.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · proportional odds model · p = <0.001 · Odds ratio (or): 4.12 · 95% CI 2.22 to 7.63Controlling for treatment group, region, and baseline OCS dose.
SecondaryPercentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL

Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Median · Percent
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL
PercentBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control for Patients With Baseline Eosinophils >=300/uL75.00 (60.00 to 100.00)75.00 (60.00 to 91.70)0.00 (0.00 to 28.60)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 50.00 · 95% CI 25.00 to 66.70Hodges Lehmann estimate is used.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Wilcoxon (Mann-Whitney) · p = <0.001 · Median difference (final values): 50.00 · 95% CI 25.00 to 66.70Hodges Lehmann estimate is used.
SecondaryThe Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control

Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Count of participants · Participants
The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Percentage of Patients With ≥50% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control484828
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 3.59 · 95% CI 1.79 to 7.22Controlling for region.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 3.03 · 95% CI 1.57 to 5.86Controlling for region.
SecondaryThe Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control

Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. The percentage reduction from baseline is defined as: {(Baseline dose-final dose)/baseline dose}\*100%. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Number · Participants
The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Proportion of Eligible Patients With ≥100% Reduction in Average Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control22228
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 5.23 · 95% CI 1.92 to 14.21Controlling for region.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.002 · Odds ratio (or): 4.19 · 95% CI 1.58 to 11.12Controlling for region.
SecondaryThe Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.

Baseline OCS dose is the dose upon which the patient is stabilised at randomisation (Week 0). Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Number · Participants
The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Proportion of Patients With ≤5.0 mg Reduction on Daily OCS Dose at Visit 14 Compared With Baseline Dose at Visit 6, While Maintaining Asthma Control.222538
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.012 · Odds ratio (or): 0.42 · 95% CI 0.21 to 0.83Controlling for region.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.053 · Odds ratio (or): 0.52 · 95% CI 0.27 to 1.01Controlling for region.
SecondaryThe Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control

Final OCS dose is the dose at Week 28. If a patient discontinues from the study during a given dose reduction period, or the patient experiences an exacerbation between Weeks 24 and 28 or immediately before discontinuation, then the final OCS dose will be 1 dose level higher than that which directly preceded the event.

Time frame:
Week 28
Reported as:
Number · Participants
The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Proportion of Patients With Average Final OCS Dose ≤5.0 mg Daily at Visit 14, While Maintaining Asthma Control444325
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 3.16 · 95% CI 1.60 to 6.23Controlling for region.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.002 · Odds ratio (or): 2.74 · 95% CI 1.41 to 5.31Controlling for region.
SecondaryNumber and Percentage of Patients With ≥1 Asthma Exacerbation

Number and percentage of patients with at least one post randomisation asthma exacerbation.

Time frame:
Immediately following the randomisation through Study Week 28
Reported as:
Count of participants · Participants
Number and Percentage of Patients With ≥1 Asthma Exacerbation
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Number and Percentage of Patients With ≥1 Asthma Exacerbation191739
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = 0.001 · Odds ratio (or): 0.32 · 95% CI 0.16 to 0.65Controlling for region.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 0.28 · 95% CI 0.14 to 0.56Controlling for region.
SecondaryTime to the First Asthma Exacerbation

Time to the first occurrence of asthma exacerbation post randomisation

Time frame:
The time from randomisation to the date of first asthma exacerbation over 28 weeks
Reported as:
Median · Days
Time to the First Asthma Exacerbation
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Time to the First Asthma ExacerbationNA (NA to NA)NA (NA to NA)155 (111 to NA)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.39 · 95% CI 0.22 to 0.66Including covariates treatment group, region, number of exacerbations in the previous year.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.32 · 95% CI 0.17 to 0.57Including covariates treatment group, region, number of exacerbations in the previous year.
SecondaryTime to the First Asthma Exacerbation Requiring Hospitalization or ER Visit

Time to the first exacerbation requiring hospitalization or ER visit post randomisation

Time frame:
The time from randomisation to the date of first asthma exacerbation associated with hospitalization or ER over 28 weeks.
Reported as:
Median · Days
Time to the First Asthma Exacerbation Requiring Hospitalization or ER Visit
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Time to the First Asthma Exacerbation Requiring Hospitalization or ER VisitNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Cox · p = 0.291 · Hazard ratio (hr): 0.53 · 95% CI 0.14 to 1.64Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Cox · p = 0.042 · Hazard ratio (hr): 0.12 · 95% CI 0.01 to 0.63Including covariates treatment group, region, any exacerbations in the previous year requiring hospitalization or ER visit.
SecondaryThe Annualized Rate of Asthma Exacerbation

The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator adjusted by the time of follow-up.

Time frame:
The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
Reported as:
Least squares mean · events/year
The Annualized Rate of Asthma Exacerbation
events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Annualized Rate of Asthma Exacerbation0.83 (0.55 to 1.26)0.54 (0.34 to 0.88)1.83 (1.33 to 2.50)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · negative binomial model · p = 0.003 · Rate ratio: 0.45 · 95% CI 0.27 to 0.76Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · negative binomial model · p = <0.001 · Rate ratio: 0.3 · 95% CI 0.17 to 0.53Including covariates treatment group, region, number of exacerbations in the previous year. The log of follow-up time is used as offset variable.
SecondaryThe Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization

The annualized exacerbation rate is based on unadjudicated exacerbation reported by the investigator that are associated with an emergency room visit or a hospitalization adjusted by the time of follow-up.

Time frame:
The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
Reported as:
Least squares mean · events/year
The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization
events/yearBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
The Annualized Rate of Asthma Exacerbations That Are Associated With an Emergency Room Visit or a Hospitalization0.14 (0.05 to 0.38)0.02 (0.00 to 0.18)0.32 (0.16 to 0.65)
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · negative binomial model · p = 0.187 · Rate ratio: 0.44 · 95% CI 0.13 to 1.49Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · negative binomial model · p = 0.018 · Rate ratio: 0.07 · 95% CI 0.01 to 0.63Covariates include treatment, region, any exacerbations in the previous year requiring hospitalization/ER. Log of follow-up time is the offset.
SecondaryNumber of Days in Hospital Due to Asthma

Number of days in hospital due to asthma, if none, 0 day is considered

Time frame:
The time from randomisation to the date of week 28 visit (end of treatment) or last contact if the patient is lost to follow up
Reported as:
Mean · Days
Number of Days in Hospital Due to Asthma
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Number of Days in Hospital Due to Asthma0.3 ± 1.410.5 ± 3.861.2 ± 6.66
SecondaryChange From Baseline to Week 28 in Pre-bronchodilator FEV1

Baseline is defined as the last non-missing value prior to the first dose of study treatment. Change from baseline to Week 28 in two treatment groups is compared to placebo group.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Liter
Change From Baseline to Week 28 in Pre-bronchodilator FEV1
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Pre-bronchodilator FEV10.230 ± 0.4290.255 ± 0.5080.114 ± 0.401
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.153 · Mean difference (final values): 0.105 · 95% CI -0.040 to 0.251Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.129 · Mean difference (final values): 0.112 · 95% CI -0.033 to 0.258Including covariates: treatment group, region, baseline pre-BD FEV1 value, visit, and visit by treatment interaction.
SecondaryChange From Baseline to Week 28 in Asthma Symptom Scores (Total)

Asthma symptoms during night time and daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma), and total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 28 in Asthma Symptom Scores (Total)
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Asthma Symptom Scores (Total)-0.58 ± 1.03-0.77 ± 1.03-0.58 ± 1.03
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.947 · Mean difference (final values): -0.01 · 95% CI -0.35 to 0.32Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.291 · Mean difference (final values): -0.18 · 95% CI -0.51 to 0.16Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in Asthma Symptom Scores (Daytime)

Asthma symptoms during daytime are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Asthma Symptom Scores (Daytime)-0.32 ± 0.56-0.44 ± 0.52-0.32 ± 0.57
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.998 · Mean difference (final values): -0.00 · 95% CI -0.18 to 0.18Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.177 · Mean difference (final values): -0.12 · 95% CI -0.30 to 0.05Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)

Asthma symptoms during night time are recorded by the patient in the asthma daily diary. Symptom score values are from 0 (No asthma symptom) to 3 (unable to sleep because of asthma, or unable to do normal activities due to asthma). Lower score (0) is indicating better asthma symptom, while higher score (3) is indicating worse asthma symptom. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each time point is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this is considered as missing. Symptom score lower is better.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Asthma Symptom Scores (Nighttime)-0.27 ± 0.51-0.34 ± 0.54-0.27 ± 0.54
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.973 · Mean difference (final values): -0.00 · 95% CI -0.17 to 0.17Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.480 · Mean difference (final values): -0.06 · 95% CI -0.23 to 0.11Include covariates: treatment group, baseline asthma symptom score, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in Rescue Medication Use

Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data. If more than 50% of scores are missing in a 14 day period then this will be considered as missing. The number of inhalations (puffs) per day will be calculated as follows: Number of night inhaler puffs + 2 x \[number of night nebulizer times\] + number of day inhaler puffs + 2 x \[number of day nebulizer times\].

Time frame:
Change from baseline at week 28
Reported as:
Mean · number of puffs per day
Change From Baseline to Week 28 in Rescue Medication Use
number of puffs per dayBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Rescue Medication Use-1.39 ± 2.86-2.58 ± 4.36-1.07 ± 2.86
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.397 · Mean difference (final values): -0.43 · 95% CI -1.44 to 0.57Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -1.41 · 95% CI -2.42 to -0.41Include covariates: treatment group, baseline total asthma rescue medication use, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)

Morning peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Liter/min
Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)
Liter/minBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Home Lung Function (Morning Peak Expiratory Flow)32.697 ± 89.45743.022 ± 73.30310.884 ± 69.356
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.143 · Mean difference (final values): 19.25 · 95% CI -6.58 to 45.07Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.023 · Mean difference (final values): 30.01 · 95% CI 4.26 to 55.76Include covariates: treatment group, baseline morning PEF, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)

Evening peak expiratory flow change from baseline to week 28. Baseline is defined as the average of data collected from the evening of study day -14 to the morning of study day 1. Each timepoint is calculated as bi-weekly means based on daily diary data

Time frame:
Change from baseline at week 28
Reported as:
Mean · Liter/min
Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)
Liter/minBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in Home Lung Function (Evening Peak Expiratory Flow)21.885 ± 83.13634.157 ± 69.2872.933 ± 72.302
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.237 · Mean difference (final values): 15.19 · 95% CI -10.08 to 40.46Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.014 · Mean difference (final values): 31.52 · 95% CI 6.32 to 56.71Include covariates: treatment group, baseline evening PEF, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication

Baseline is defined as the proportion of nights from the evening of study day -14 to the morning of study day 1.Each timepoint is calculated as bi-weekly proportions based on daily diary data. If more than 50% of data are missing in a 14 day period then this will be considered as missing.Proportion of nights with noctural awakenings is defined as the number of nights with awakenings due to asthma and requiring rescue medication divided by number of nights with data.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Proportion
Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication
ProportionBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in the Proportion of Nights With Awakening Due to Asthma Requiring Rescue Medication-0.158 ± 0.283-0.2 ± 0.337-0.186 ± 0.344
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.742 · Mean difference (final values): 0.02 · 95% CI -0.08 to 0.11Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.693 · Mean difference (final values): -0.02 · 95% CI -0.11 to 0.07Including covariates: treatment group, baseline proportion of nights with noctural awakenings, region, visit, and treatment by visit interaction.
SecondaryChange From Baseline to Week 28 in ACQ-6

ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses. Mean scores of \<=0.75 indicates well-controlled asthma, scores between 0.75 to \<=1.5 indicate partly controlled asthma, and \>1.5 indicates not well controlled asthma.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Scores on a scale
Change From Baseline to Week 28 in ACQ-6
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline to Week 28 in ACQ-6-0.86 ± 0.95-1.09 ± 1.09-0.68 ± 1.10
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.139 · Mean difference (final values): -0.24 · 95% CI -0.55 to 0.08Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.001 · Mean difference (final values): -0.55 · 95% CI -0.86 to -0.23Include covariates: treatment group, baseline ACQ-6 score, region, visit, and treatment by visit interaction.
SecondaryACQ-6 Responders (Improvement) at Week 28

Improvement is defined as ACQ-6 (End of treatment - baseline) \<= -0.5. No change is defined as ACQ-6 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as ACQ-6 (End of treatment - baseline) \>= 0.5. ACQ-6 score is defined as the average of the first 6 items of the ACQ questionnaire on symptoms, activity limitations and rescue medication.Scores range from 0 (totally controlled) to 6 (severely uncontrolled). Baseline is defined as the last non-missing value prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable ACQ-6 at week 28 are considered non-responder.

Time frame:
Week 28
Reported as:
Number · Participants
ACQ-6 Responders (Improvement) at Week 28
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
ACQ-6 Responders (Improvement) at Week 2841 ± 0.9546 ± 1.0941 ± 1.10
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Logistic · p = 0.658 · Odds ratio (or): 1.165 · 95% CI 0.592 to 2.295Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Logistic · p = 0.155 · Odds ratio (or): 1.661 · 95% CI 0.826 to 3.340Including covariates: treatment group, baseline ACQ-6 score, region, number of exacerbations in the previous year.
SecondaryChange From Baseline at Week 28 in AQLQ(S)+12 (Overall)

AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment). Total or domain score change of \>=0.5 are considered clinically meaningful.

Time frame:
Change from baseline at week 28
Reported as:
Mean · Scores on a scale
Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)
Scores on a scaleBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Change From Baseline at Week 28 in AQLQ(S)+12 (Overall)0.90 ± 0.931.05 ± 1.040.67 ± 1.10
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = 0.151 · Mean difference (final values): 0.23 · 95% CI -0.08 to 0.53Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = 0.004 · Mean difference (final values): 0.45 · 95% CI 0.14 to 0.76Including covariates: treatment group, region, baseline AQLQ(S)+12 score, visit, and treatment by visit interaction.
SecondaryAQLQ(s)+12 Responders (Improvement) at Week 28

AQLQ(S)+12 overall score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. Improvement is defined as AQLQ(S)+12 (End of treatment - baseline)\>=0.5. No change is defined as AQLQ(S)+12 (End of treatment - baseline) \>-0.5 and \<0.5. Deterioration is defined as AQLQ(S)+12 (End of treatment - baseline) \<= -0.5. Baseline is defined as the last AQLQ(S)+12 score prior to randomisation. End of treatment is defined as week 28. Patients with missing or non-evaluable score at week 28 are considered as non-responder.

Time frame:
Week 28
Reported as:
Number · Participants
AQLQ(s)+12 Responders (Improvement) at Week 28
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
AQLQ(s)+12 Responders (Improvement) at Week 2843 ± 0.9544 ± 1.0939 ± 1.10
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Regression, Logistic · p = 0.220 · Odds ratio (or): 1.538 · 95% CI 0.773 to 3.060Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Regression, Logistic · p = 0.108 · Odds ratio (or): 1.783 · 95% CI 0.882 to 3.605Including covariates: treatment group, region, baseline AQLQ(S)+12 score, number of exacerbations in the previous year.
SecondaryExtent of Exposure

Duration of exposure from first dose date to last dose date.

Time frame:
From first dose to Week 24
Reported as:
Mean · Days
Extent of Exposure
DaysBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Extent of Exposure162.53 ± 30.09159.77 ± 35.781167.05 ± 10.697
SecondarySerum Concentration of Benralizumab

Pre-dose serum concentrations at each visit

Time frame:
Pre-first dose to Week 36
Reported as:
Geometric mean · ng/mL
Serum Concentration of Benralizumab
ng/mLBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Baseline (n=69, 71)NA ± NANA ± NA—
Week 4 (n=67, 71)804.37 ± 52.77721.42 ± 52.30—
week 8 (n=66, 69)1152.96 ± 53.161019.65 ± 89.51—
Week 12 (n=68, 67)1319.14 ± 66.051057.91 ± 125.74—
Week 16 (n=67,67)1337.98 ± 118.90303.54 ± 144.53—
Week 24 (n=65, 66)1162.62 ± 151.35185.17 ± 278.32—
Week 28 (n=65, 65)1125.96 ± 173.79684.57 ± 205.67—
Week 36 (n=2, 4)11.11 ± 2140.875.92 ± 1230.68—
SecondaryAnti-drug Antibody Response

Number and percentage of patients in different ADA response categories

Time frame:
From baseline to follow-up Week 36
Reported as:
Count of participants · Participants
Anti-drug Antibody Response
ParticipantsBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Positive at any visit576
Baseline and Post-baseline Postive003
Only post-baseline positive563
Only baseline positive010
Persistently positive465
Transient positive101
SecondaryPercent Change From Baseline in Blood Eosinophil Counts

Percent change from baseline in blood eosinophil counts at week 28

Time frame:
Change from baseline at Week 28
Reported as:
Mean · percent change
Percent Change From Baseline in Blood Eosinophil Counts
percent changeBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Percent Change From Baseline in Blood Eosinophil Counts-97.4 ± 12.93-94.9 ± 16.5445.5 ± 239.51
Statistical analysis
  • Benralizumab 30 mg q.4 Weeks vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -162.2 · 95% CI -220.1 to -104.3Percent change
  • Benralizumab 30 mg q.8 Weeks vs Placebo · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -159.4 · 95% CI -217.9 to -100.9Percent change
SecondaryTotal Lung Capacity

Change from baseline in total lung capacity

Time frame:
From baseline to Week 28
Reported as:
Mean · Liter
Total Lung Capacity
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Week 12 (n=17, 23, 17)-0.02 ± 0.95-0.07 ± 0.68-0.30 ± 1.08
Week 28 (n=14, 18, 15)0.11 ± 1.31-0.21 ± 0.70-0.47 ± 1.47
SecondaryResidual Volume

Change from baseline in residual volume

Time frame:
From baseline to Week 28
Reported as:
Mean · Liter
Residual Volume
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Week 12 (n=17, 23, 17)0.02 ± 1.00-0.22 ± 0.74-0.35 ± 1.03
Week 28 (n=14, 18, 15)0.07 ± 1.34-0.31 ± 0.71-0.41 ± 1.27
SecondaryVital Capacity

Change from baseline in vital capacity

Time frame:
From baseline to Week 28
Reported as:
Mean · Liter
Vital Capacity
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Week 12 (n=17, 24, 18)0.15 ± 0.800.18 ± 0.350.13 ± 0.89
Week 28 (n=14, 18, 15)0.15 ± 0.410.11 ± 0.48-0.08 ± 0.41
SecondaryFunctional Residual Capacity

Change from baseline in functional residual capacity

Time frame:
From baseline to Week 28
Reported as:
Mean · Liter
Functional Residual Capacity
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Week 12 (n=17,23, 18)-0.05 ± 1.06-0.09 ± 0.74-0.38 ± 0.99
Week 28 (n=13,18, 15)-0.15 ± 1.49-0.26 ± 0.74-0.43 ± 1.25
SecondaryInspiratory Capacity

Change from baseline in inspiratory capacity

Time frame:
From baseline to Week 28
Reported as:
Mean · Liter
Inspiratory Capacity
LiterBenralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlacebo
Week 12 (n=17, 23, 17)0.44 ± 1.220.14 ± 0.88-0.01 ± 0.40
Week 28 (n=14, 17, 15)0.52 ± 1.160.09 ± 1.01-0.02 ± 0.40

Adverse events

Collected over Include events occurred from the start of study treatment to the end of study (up to 36 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg q.4 Weeks—7/72 (9.7%)34/72 (47.2%)
Benra 30 mg q.8 Weeks—7/73 (9.6%)34/73 (46.6%)
Placebo—14/75 (18.7%)49/75 (65.3%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders3/721/734/75
PneumoniaInfections and infestations0/722/733/75
Status asthmaticusRespiratory, thoracic and mediastinal disorders0/720/733/75
InfluenzaInfections and infestations0/720/732/75
Umbilical herniaGastrointestinal disorders1/720/730/75
Adverse drug reactionGeneral disorders1/720/730/75
HypersensitivityImmune system disorders1/720/730/75
Urinary tract infection bacterialInfections and infestations1/720/730/75
UrosepsisInfections and infestations1/720/730/75
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/720/730/75
Most frequent other events
Showing 10 of 15
Most frequent other events
EventBenra 30 mg q.4 WeeksBenra 30 mg q.8 WeeksPlacebo
NasopharyngitisInfections and infestations11/7212/7315/75
AsthmaRespiratory, thoracic and mediastinal disorders6/721/7314/75
BronchitisInfections and infestations5/728/7312/75
SinusitisInfections and infestations5/724/738/75
RhinitisInfections and infestations2/726/732/75
HeadacheNervous system disorders5/726/734/75
Upper respiratory tract infectionInfections and infestations4/725/735/75
InfluenzaInfections and infestations3/721/735/75
Oral candidiasisInfections and infestations0/720/734/75
Back painMusculoskeletal and connective tissue disorders2/722/734/75

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Mean50.2 ± 12.052.9 ± 10.149.9 ± 11.751.0 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mg q.4 WeeksBenralizumab 30 mg q.8 WeeksPlaceboTotal
Female404748135
Male32262785
08

Study locations

87 sites
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Centennial, Colorado 80112, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Hialeah, Florida 33010, United States
  • Research Site
    Hialeah, Florida 33013, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Orlando, Florida 32825, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Fort Mitchell, Kentucky 41017, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Durham, North Carolina 27704, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45231, United States
  • Research Site
    Middleburg Heights, Ohio 44130, United States
  • Research Site
    Oklahoma City, Oklahoma 73112, United States
  • Research Site
    Philadelphia, Pennsylvania 19140, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Buenos Aires, C1414AIF, Argentina
  • Research Site
    Caba, 1426, Argentina
  • Research Site
    Florida, 1638, Argentina
  • Research Site
    Mendoza, 5500, Argentina
  • Research Site
    Kozloduy, 3320, Bulgaria
  • Research Site
    Pazardzhik, 4400, Bulgaria
  • Research Site
    Petrich, 2850, Bulgaria
  • Research Site
    Ruse, 7002, Bulgaria
  • Research Site
    Samokov, 2000, Bulgaria
  • Research Site
    Vratsa, 3000, Bulgaria
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Hamilton, Ontario L8N 4A6, Canada
  • Research Site
    Ottawa, Ontario K1G 6C6, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Quebec, G1V 4G5, Canada
  • Research Site
    Quillota, Chile
  • Research Site
    Rancagua, 2820000, Chile
  • Research Site
    Santiago, 8380453, Chile
  • Research Site
    Talcahuano, 4270918, Chile
  • Research Site
    Talca, 3465584, Chile
  • Research Site
    Valparaiso, 2341131, Chile
  • Research Site
    Brest Cedex 2, 29609, France
  • Research Site
    Lyon Cedex 04, 69317, France
  • Research Site
    Marseille, 13015, France
  • Research Site
    Montpellier, 34295, France
  • Research Site
    Strasbourg Cedex, 67091, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Bamberg, 96049, Germany
  • Research Site
    Berlin, 10119, Germany
  • Research Site
    Freiburg, 79106, Germany
  • Research Site
    Grosshansdorf, 20927, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Leipzig, 04207, Germany
  • Research Site
    Mainz, 55131, Germany
  • Research Site
    Seoul, 02559, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 03722, Korea, Republic of
  • Research Site
    Seoul, 06591, Korea, Republic of
  • Research Site
    Seoul, 135-710, Korea, Republic of
  • Research Site
    Suwon-si, 16499, Korea, Republic of
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Karczew, 05-480, Poland
  • Research Site
    Koszalin, 75-679, Poland
  • Research Site
    Kraków, 31-011, Poland
  • Research Site
    Kraków, 31-159, Poland
  • Research Site
    Lubin, 59-300, Poland
  • Research Site
    Szczecin, 70-111, Poland
  • Research Site
    Tarnów, 33-100, Poland
  • Research Site
    Trzebnica, 55-100, Poland
  • Research Site
    Wroclaw, 53-201, Poland
  • Research Site
    Wrocław, 53-301, Poland
  • Research Site
    Łódź, 90-141, Poland
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Valencia, 46017, Spain
  • Research Site
    Adana, 01330, Turkey
  • Research Site
    Ankara, 06230, Turkey
  • Research Site
    Bursa, Turkey
  • Research Site
    Istanbul, 34098, Turkey
  • Research Site
    İstanbul, 34844, Turkey
  • Research Site
    Dnipropetrovsk, 49007, Ukraine
  • Research Site
    Ivano-Frankivsk, 76012, Ukraine
  • Research Site
    Kharkiv, 61035, Ukraine
  • Research Site
    Kharkiv, 61039, Ukraine
  • Research Site
    Kyiv, 03680, Ukraine
  • Research Site
    Kyiv, 04201, Ukraine
  • Research Site
    Vinnytsia, 21029, Ukraine
09

References and documents

Publications

  • Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M; ZONDA Trial Investigators. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22. PubMed 28530840 ↗
  • Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv Ther. 2022 May;39(5):2065-2084. doi: 10.1007/s12325-022-02098-1. Epub 2022 Mar 14. PubMed 35287231 ↗
  • Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3):00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul. PubMed 31579676 ↗
  • Chupp G, Lugogo NL, Kline JN, Ferguson GT, Hirsch I, Goldman M, Zangrilli JG, Trudo F. Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2019 May;122(5):478-485. doi: 10.1016/j.anai.2019.02.016. Epub 2019 Feb 23. PubMed 30802500 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Aug 2016, 27 months.

Results were first posted in Oct 2017, 1 year 2 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 27 months is close to that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Mar 3, 2014
StartActual
Apr 28, 2014
Primary completionActual
Aug 8, 2016
CompletionActual
Aug 8, 2016
Results first posted
Oct 17, 2017
Last update
Jun 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02075255
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 3, 2014
Start date
Apr 28, 2014
Primary completion
Aug 8, 2016
Completion
Aug 8, 2016
Results posted
Oct 17, 2017
Last update
Jun 8, 2018

Study contacts

Parameswaran Nair, MD,PhD,FRCP,FRCPC
principal investigator · St Joseph's Healthcare Hamilton Firestone Institute for Respiratory Health 50 Charlton Avenue East Hamilton

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion